Animal Health CDMO Services

Biologics, Cost-Smart Manufacturing │ Global Regulatory Readiness

Elise Biopharma is a full-stack Animal Health CDMO built to translate veterinary concepts into licensable, field-ready biologics. We combine microbial, mammalian, and RNA platforms with formulation science, analytics, and regulatory authorship—under a single digital QMS. Whether you’re advancing mRNA veterinary vaccines, monoclonal antibodies for animals (mAbs), subunit/enzymatic therapeutics, live or inactivated vaccines, phage-based products, or probiotics & synbiotics, our job is simple: compress timelines, de-risk scale-up, and deliver material that works in the field, not only in the lab.

Why a Dedicated Animal Health CDMO?

Veterinary biologics face all the complexities of human biotherapeutics—plus species biology, fragmented global standards, cold-chain challenges, and cost pressures that punish over-engineering. Elise resolves this by pairing human-grade manufacturing rigor with species-aware pragmatism:

Species fit, first. Canine, feline, equine, bovine, ovine/caprine, swine, poultry, aquaculture, camelids, and exotics each drive different dose forms, excipients, and QC.
Regulatory bifurcation handled. In the U.S., many vaccines and immunologicals route via USDA APHIS Center for Veterinary Biologics (CVB); monoclonal antibodies for animals typically route via FDA Center for Veterinary Medicine (CVM); EU programs involve EMA/CVMP and national authorities. We plan documents and data accordingly.
Cost-of-goods engineered in. We prioritize platform processes, single-use wherever it reduces risk/cost, and analytics that answer regulatory questions once—not five times.

What We Make (Modalities & Use Cases)

Vaccines & Immunoprophylaxis

mRNA veterinary vaccines (mRNA/saRNA → LNP; mucosal possibilities when justified)
Recombinant subunit vaccines (microbial, yeast, or insect)
VLPs (insect/baculovirus or yeast)
Live attenuated / inactivated (process development, upstream/downstream/kill steps)
Bacterins, toxoids, autogenous vaccines (where permitted)

Therapeutic & Preventive Biologics

Monoclonal antibodies for animals (mAbs) — CHO/fed-batch or perfusion; species-tuned Fc; long-acting designs
Fc-fusions / multispecifics / fragments (VHH, Fab, scFv) for companion animals and equine
Enzyme therapeutics & recombinant cytokines (microbial or mammalian)
Phage therapeutics & bacteriocins (feed/water dosing, topical, or oral delivery)
Exosome & EV products (exploratory programs under research-grade or cGMP-like controls)

Microbiome & Nutrition

Probiotics & synbiotics for gut health and pathogen exclusion (companion, poultry, swine, aquaculture)
Precision fermentation of bioactives and feed enzymes (thermostable options for pelleting)

Diagnostics & Reagents (Adjacency)

Antigens & controls for veterinary assays
RUO → IVD roadmaps with ISO 13485 design controls when you also need an IVD CDMO stance

Platform Continuum (One Site, One QMS)

1) Molecular Biology & Template Enablement

(For teams seeking an upstream partner and “molecular biology cdmo services” to prime manufacturability.)

Sequence design and codon/GC tuning by host; 5′/3′ UTR and poly(A) strategies for RNA; signal peptides for secreted proteins
Vector selection (copy number, promoters), library construction, and high-throughput screening
Plasmid DNA generation (research → GMP), sequence confirmation, supercoil ratio control
Documentation that flows downstream (traceability, genealogy, release criteria)

2) Microbial Systems (Cost-Smart Scale)

E. coli, Bacillus, and Pichia (Komagataella) with secretion/solubility engineering
Fed-batch intensification; oxygen-transfer modeling; overflow metabolism mitigation
Inclusion body strategies with refold design when it wins on COGS
Downstream: capture (IEX/IMAC), polishing (AEX/CEX/HIC), endotoxin management, and consistent bulk formulation.

Gecko, CDMO Animal Health, Elise Biopharma

3) Mammalian Systems (mAbs & Complex Proteins)

CHO line development (transient → stable), clone selection, stability studies
Fed-batch or perfusion; protein A/alt-A capture; glycoengineering for species FcγR interactions (e.g., ADCC tuning for canine/equine targets)
Process characterization (DoE), viral clearance validation strategies, and comparability plans for late-phase

4) Insect & Yeast for VLPs/Subunits

Sf9/baculovirus VLP production and purification (density gradients → scalable chromatography)
Yeast subunits with strong thermostability profiles for field inoculation campaigns

5) In Vitro RNA (Veterinary Vaccines)

IVT mRNA / saRNA with dsRNA minimization; LNP sizing via microfluidics with real-time DLS feedback (size/PDI/encapsulation as CQAs)
Aseptic fill, cold chain or lyophilized LNP option if justified by data
Direct bridge to our in vitro biology services cdmo layer for potency/transfection readouts

6) Formulation, Dose-Form, and Fieldability

Injectables: IM/SC, viscosity control for large-animal dosing, preservative strategy
Oral: microencapsulation for rumen bypass or gastric survival; pelleting heat-tolerance
Mucosal: intranasal/oral drench where immunogenicity profile supports it
Aquaculture: immersion/immersion-boost + feed coatings that don’t break water quality limits
Stability: real-time/accelerated; freeze-thaw; agitation; photostability (field transport simulation)

mAbs for Animals: From Concept to Clinic-Equivalent Supply

Use cases: allergy/dermatology in dogs and cats, osteoarthritis pain modulation, infectious disease neutralization, antitoxins, and oncology supportive care.

Cell line development (CHO). Transient expression for sequence screen → stable pools → clonal isolates with productivity/quality windows defined early.
Fc engineering. Species isotypes and FcRn binding tuned for half-life; afucosylation/galactosylation options for effector modulation.
Manufacturing. Fed-batch for flexibility; perfusion for high-throughput campaigns; Protein A or alternative capture to meet cost goals.
Analytics. Identity (LC-MS), charge/size variants (icIEF/SEC-MALS), glycan profiles, binding/neutralization, ADA risk screens, potency in species-relevant systems.
Regulatory posture. CVM (FDA) pathways in the U.S. for mAbs; EMA/CVMP in EU; global alignment on pharmacovigilance and labeling.
Dose-form & stability. Multi-dose vials with antimicrobial strategy where appropriate; autoinjector feasibility for companion animals; CCI & extractables/leachables.

Vaccines Done for the Real World

Thermostability first. We design toward cold-chain realities; lyophilization or stabilizer matrices where evidence supports it.
Adjuvants rationally used. Alum, saponin, emulsions, TLR agonists—chosen by species, route, and tolerability.
Potency methods that survive the field. Species-relevant neutralization and cell-based assays; bridging plans when models evolve.
Campaign manufacturing. Seasonal scaling, serial release logic, and distribution cadence planning with your field team.

Phage, Bacteriocins, and Microbiome Programs

Phage therapeutics. Cocktail design (MOI/host range), propagation and purification, endotoxin control strategies for parenteral/topical/oral use; stability around feed processing.
Bacteriocins. Fermentation with secretion where possible; purification schemes that avoid harsh solvents; activity assays in target matrices.
Probiotics & synbiotics. Strain selection, spore formers for feed durability, co-encapsulation with prebiotics, cGMP production and packaging for farm logistics.

Analytics & Release (Species-Aware and Audit-Ready)

Identity & Purity

Mass spectrometry (intact/subunit), peptide mapping; CE-SDS/NR-CE-SDS; residual nucleic acids/proteins; endotoxin and bioburden/sterility

Potency & Function

Cell-based mechanisms, receptor binding/neutralization, enzyme activity under species pH/ionic conditions, opsonization/ADCC/CDC (when relevant)

Safety & Stability

Preservative efficacy (multi-dose vials), extractables/leachables, osmolality/pH/viscosity windows, agitation and temperature excursions that mirror transport

RNA-specific (mRNA veterinary vaccines)

dsRNA content (ELISA/dot-blot), cap structure and poly(A), LNP size/PDI/encapsulation, residual solvents, potency by transfection expression readouts

Lot Release Packages

CoA, executed batch records (21 CFR Part 11), deviations/CAPA, stability plans, and serial release data aligned with destination authority

Quality & Regulatory (Built for USDA CVB, FDA CVM, EMA/CVMP)

QMS. cGMP with electronic batch records (Part 11), ALCOA+ data integrity, change control, CAPA, supplier qualification, and environmental monitoring.
USDA CVB. Outline of Production logic, serial release planning, and conditional licensure support for immunologicals where appropriate.
CVM (FDA). Chemistry, manufacturing, and controls packages for mAbs and therapeutic biologics; comparability strategies across lifecycle.
EMA/CVMP & global. EU dossier quality modules, validated methods, and QP-friendly documentation; VICH-aligned safety/efficacy expectations.
Disclaimer: Regulatory strategy varies by product class and jurisdiction; we tailor a plan with your counsel and scientific leads.

Process by Design (QTPP → CQA → CPP) with PAT

QTPP examples: target species, route (IM/SC/oral/mucosal), dose strength and volume, shelf life, re-use (multi-dose vial)
CQAs examples: potency window, size/PDI (LNPs), glycan profile (mAbs), endotoxin, residual solvents/preservatives, viscosity, stability at target temperature
CPPs examples: DO/feed/induction (microbial), perfusion rate and bleed (CHO), FRR/TFR and total lipid (LNP), pH/temp ramps (vaccines), lyophilization cycles

PAT & Digital Layer

Inline pH/DO/temperature and at-line HPLC/UPLC; closed-loop DLS for LNP size control; exception-based batch review; automated CoA generation; CPV dashboards for commercial programs

Facilities & Scale

Upstream: microbial (2 L → 2,000 L), mammalian (2 L → 2,000 L fed-batch; perfusion options), insect/yeast for VLPs and subunits
Downstream: depth filtration, TFF, chromatography (IEX/AEX/CEX/HIC/Protein A/alt-A), virus inactivation/clearance logic for mammalian biologics
Fill/Finish: ISO 5 isolators, vials and PFS, nitrogen overlay; low-shear paths for LNPs and delicate proteins; lyophilization where supported
Stability: ICH and field-simulation chambers (including heat spikes and shake profiles)

Program Onboarding (30/60/90)

Day 0–30

Intake & risk register (species, route, dose economics)
QTPP/CQA/CPP alignment workshop; analytical gap list
DoE plans for yield/quality and fieldability (e.g., viscosity, preservative, or thermostability)

Day 31–60

Unit-op sprints (upstream/downstream/formulation) with PAT configuration
Potency assay establishment (in vitro biology services cdmo layer)
Interim review with go/no-go criteria tied to CQAs

Day 61–90

Lock control strategy for pilot or first GLP/GMP runs
Stability protocol launch
Draft regulatory outline (USDA CVB/CVM/EMA) and preliminary dossier tables

Engagement Models

Template-to-Field Pilot (non-GMP, 3–5 months): materials for preclinical and first field trials; mini-CMC packet
Gene-to-Licensure (GMP, 9–15 months): DS/DP for pivotal trials; method qualification/validation; dossier authoring support
Commercial Ramp (program-dependent): PPQ, CPV, dual-site strategy, demand forecasting, and cost-of-goods optimization

Cost-of-Goods (COGS) & Supply Strategy

Early COGS modeling to target price-per-dose; sensitivity to raw materials, yields, and cycle times
Platform reuse across your portfolio (shared methods/specs) to reduce marginal cost
Campaign planning for seasonal diseases and regional rollouts; serial release cadence designed with your logistics teams

Tech Transfer & Network-Ready Documentation

Complete TT dossiers (unit ops, CPPs, equipment/consumables, edge-case library)
Comparison matrices for receiving-site qualification; onsite/remote support options
Continued Process Verification tools that travel with the process

Animal Health CDMO — Frequently Asked Questions (20)

Q1) Can you support both USDA CVB and FDA CVM pathways (and EU analogs)?

Yes. Vaccines and most immunologicals typically route via USDA APHIS Center for Veterinary Biologics (CVB); therapeutic biologics such as monoclonal antibodies for animals generally route via FDA Center for Veterinary Medicine (CVM). For EU programs, we align with EMA/CVMP and applicable national authorities. We scope regulatory strategy up front, map CMC sections to the right authority, and write dossiers so they’re region-portable. For CVB immunologicals we plan Outline of Production, serial release, and conditional licensure options; for CVM biologics, we align comparability and validation depth to phase. This split governance is a core reason to choose a species-aware Animal Health CDMO.

Q2) How do you engineer “field stability” for veterinary biologics?

We design for fieldability from day one: stabilizer screens, lyophilization feasibility when justified, and stress profiles that mimic farm transport (heat spikes, vibration, light). For oral/feed applications we simulate pelleting and storage humidity; for aquaculture we evaluate immersion stability. Release and stability are stability-indicating (potency, size/PDI for LNPs, encapsulation, sterility, endotoxin, appearance). We convert results into label claims and shipping SOPs your distributors can actually meet.

Q3) Do you handle mAbs for animals end-to-end?

Yes—CHO line development → process development (fed-batch/perfusion) → full analytics → fill-finish → stability → dossier support. Species fit matters, so we tune Fc (glycans, FcRn interactions) for canine/feline/equine pharmacology and dose intervals. Analytics include identity (LC-MS), variants (icIEF/SEC-MALS), glycan profiles, binding/neutralization, and ADA risk screens. For cost control we evaluate Protein A alternatives and continuous polishing without compromising release statistics. This is one reason sponsors select an Animal Health CDMO rather than a human-only CDMO.

Q4) Can you run mRNA veterinary vaccines (mRNA/saRNA)?

Yes. We operate IVT mRNA/saRNA with dsRNA control, microfluidic LNP sizing under PAT (closed-loop DLS), aseptic fill, and ICH-aligned stability. We adapt dose/route (IM/SC/mucosal), particle size, and excipients for species tolerability and immunogenicity. Potency is measured via our in vitro biology services CDMO layer (transfection expression, innate sensing panels) with bridging plans to in-vivo readouts. Documentation covers CVB expectations for vaccines and EMA/CVMP in the EU.

Q5) What about veterinary diagnostics and reagent kits (IVD CDMO stance)?

We support RUO → IVD transitions under ISO 13485 with design controls, ISO 14971 risk management, verification/validation, and traceability. We keep therapeutic and diagnostic documentation separate but synchronized so audits stay crisp. If you’re running paired drug-diagnostic development, we establish shared analytics to avoid duplication and to accelerate submissions. This integrated IVD CDMO posture is useful for antigen controls, reference reagents, and kit components.

Q6) How do you keep veterinary COGS down without risking quality?

We practice platform engineering (reusable unit ops/specs), right-sized analytics per phase, and single-use where it reduces cost/risk. Early COGS modeling informs vessel size, cycle times, and raw material strategy; we plan campaign manufacturing for seasonal demand. PAT drives fewer optimization cycles, and packaging choices (e.g., multi-dose vials, preservative strategy) are priced into the design. The target is price-per-dose that fits the market and survives inspection.

Q7) Which species do you cover and how do species differences impact development?

We routinely support canine, feline, equine, bovine, ovine/caprine, swine, poultry, aquaculture, camelids, and exotics. Species differences drive dose/volume, injection viscosity, adjuvant choice, and potency models. For ruminants, oral formulations may require rumen-bypass microencapsulation; for poultry, mass administration impacts formulation and stability; for aquaculture, water chemistry and biomass exposure matter. We tailor CQAs and release specs to those realities—not human defaults.

Q8) What scales can you run for animal health programs?

Microbial: 2–10 L (bench), 50–200 L (pilot), 500–2,000 L (GMP).
Mammalian (CHO): 2–50 L dev, 200–2,000 L GMP, with perfusion for high-throughput campaigns.
IVT mRNA: 0.5–50 L (100 L on request), with matched purification and LNP capacity.
We plan serial release for multi-site field trials, and scale decisions are a function of dose math, stability, and price-per-dose, not just tank availability.

Q9) How do you design potency assays for veterinary labels?

We start with mechanism-linked in-vitro assays (binding/neutralization, enzyme activity) and species-relevant cell models. For vaccines, neutralization or cell-mediated readouts are staged to bridge to in-vivo correlates. Assays move from screening → qualified → validated with acceptance criteria tied to CQAs and the intended label claim. This is where our in vitro biology services CDMO offering keeps timelines tight and regulators satisfied.

Q10) What’s your adjuvant strategy for veterinary vaccines?

We build an adjuvant matrix by species, route, and tolerability: alum, saponins, emulsions, and TLR agonists where indicated. We compare potency gains with reactogenicity and COGS, then pick the lowest-risk path that meets the protection target. For sensitive species or mucosal routes, we bias toward gentler systems and use delivery geometry (e.g., LNP size) to compensate. All choices are recorded in the risk register and CMC narrative.

Q11) Do you support oral and mucosal delivery (companion, livestock, aquaculture)?

Yes. For oral we use microencapsulation and polymer matrices for rumen bypass or gastric survival; for aquaculture, immersion/dip with feed coatings; for mucosal vaccines, intranasal/oral drench with stability screens. We test palatability, uniform dosing, and residue risks where applicable. Release methods consider matrix interference (feed/serum/water) to prevent false failures.

Q12) Can you develop phage therapeutics and bacteriocins for animal use?

We do. We design phage cocktails (MOI/host range), propagate under controlled conditions, and purify with endotoxin management appropriate to route (oral/topical/parenteral). For bacteriocins, we engineer secretion or robust refold/purification steps and run activity assays in target matrices. Regulatory pathways vary by jurisdiction, so we build a dossier that explains safety, specificity, and manufacturing controls with VICH-aware language.

Q13) How do you approach probiotics & synbiotics for veterinary markets?

We select strains for durability (spore formers when needed), co-encapsulate prebiotics, and validate survivability through feed processing (pelleting). Stability includes viable count over shelf life under farm conditions. We manage contaminant risk and cross-feed issues in multi-strain mixes. Manufacturing is run under cGMP or food-grade controls as appropriate, with clear labeling support for claims.

Q14) How do you coordinate multi-site field trials and serial release?

We set batch coding and genealogy, stagger serial releases aligned to study timelines, and define reserve samples for investigations. Packaging, labels, and chain-of-custody match site SOPs; we simulate lane temperatures and handling. Data flow into a dashboard so program managers can see inventory, expiry, and site allocations in real time. This is crucial for seasonal diseases and geographically distributed trials.

Q15) What does tech transfer look like (incoming or outgoing)?

We require a structured TT dossier (unit ops, CPPs, consumables, edge cases), then run engineering lots to reproduce CQAs before optimizing. For outgoing TT (to a second site or CM), we prepare network-ready documentation: equipment maps, control ranges, PAT set-points, edge-case library, and CPV templates. A pre-agreed comparability protocol brackets any changes and preserves regulatory continuity.

Q16) What quality systems and data integrity controls are in place?

We operate under cGMP with electronic batch records (21 CFR Part 11), ALCOA+ data integrity, change control, CAPA, and environmental monitoring. Fill-finish occurs in ISO 5 isolators; upstream/downstream areas meet classified requirements per phase. QA reviews are exception-based with automated CoA generation. This digital posture is why sponsors favor us as their Animal Health CDMO.

Q17) How do you structure stability programs for veterinary labels?

We run ICH real-time and accelerated stability, plus freeze-thaw, agitation, and temperature excursion studies that reflect the field. Test points include potency, size/PDI/encapsulation (for LNPs), sterility, endotoxin, pH/osmolality, and appearance. For lyophilized formats we validate reconstitution performance. Results become expiry dating proposals and transport instructions compatible with distributors’ lanes.

Q18) What fill-finish and packaging formats do you support (and preservative strategy)?

We offer vials and prefilled syringes; for high-throughput field use, multi-dose vials with preservative efficacy (e.g., USP <51>) where supported by data. We perform CCI, particulates/visual inspection, and low-shear filling for fragile LNPs/proteins. For companion animals, we can explore autoinjector feasibility; for livestock, ruggedized packaging and labeling for barn conditions.

Q19) What timelines should we expect from kickoff to licensable supply?

Indicative timelines (program-dependent): Template-to-Field Pilot (non-GMP): 3–5 months; Gene-to-Licensure (GMP): 9–15 months covering DS/DP, method lifecycle, and dossier authoring; Commercial Ramp adds PPQ/CPV and (if needed) dual-site readiness. Drivers are method readiness, stability targets, fill-finish slots, and regulatory meeting cadence. We work in 2–4-week sprints with evidence-based gates so delay sources are visible early.

Q20) How do you price and engage (and can milestones be gated by evidence)?

We price by work-package (unit ops + analytics) with phase gates tied to CQAs (e.g., dsRNA threshold, LNP size/PDI window, potency spec). You fund learning that moves the program, not idle cycles. Multi-asset portfolios benefit from platform economics (shared methods/control strategy). If you require fixed-fee with change-control, we support it; for dynamic programs, evidence-gated milestones keep speed and quality aligned.

Deliverables You Can Expect

Technical: QbD maps, DoE reports, batch records (Part 11), CoAs, stability packages, comparability plans
Regulatory: quality module drafts, Outline of Production logic (USDA), method qualification/validation packets, PPQ/CPV frameworks
Operational: project plans with evidence-based gates, CPV dashboards, tech-transfer dossiers, supply & campaign plans

Conclusions

If you need an Animal Health CDMO that speaks the language of species, field deployment, and price-per-dose—without conceding quality or speed—Elise Biopharma is the partner of record. We don’t just manufacture; we engineer fieldable biologics: from monoclonal antibodies for animals (mAbs) and recombinant proteins to mRNA veterinary vaccines built on our in vitro mRNA synthesis CDMO platform (yes, including the full ivt mrna synthesis services cdmo. scope). Bring us your target species, route, and price point; we’ll return a 30/60/90-day execution plan with unit operations, analytics, and USDA CVB / FDA CVM / EMA-CVMP milestones locked to decision gates.

Choose the CDMO that operates like a product company. Elise Biopharma unifies molecular biology cdmo services, in vitro biology services cdmo, LNP formulation, and aseptic fill—under a single digital QMS—so your program moves from Design → Data → Decision with fewer cycles and stronger dossiers. If you’re benchmarking IVD CDMO rigor for diagnostics adjacencies—or scaling vaccines for herd-level deployment—we’ll give you audit-ready documentation, stable supply, and price-per-dose that wins in the market. Let’s build the veterinary pipeline others will try to copy.

Elise Biopharma — Animal Health CDMO Services
Species-Aware Biologics │ Cost-Smart Manufacturing │ Global Regulatory Readiness

Email our team today at info@elisebiopharma.com